Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laboratorios Farmaceuticos Rovi's operating cash flow per share for the
three
months ended in Jun. 2026 was $1.83.
Laboratorios Farmaceuticos Rovi's operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2026 was $5.77.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Laboratorios Farmaceuticos Rovi was 85.50% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -6.30% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 20.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's Operating Cash Flow per Share or its related term are showing as below:
LABFF'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -34.5 Med: 14.5 Max: 164.6
Current: -6.3
During the past 13 years, Laboratorios Farmaceuticos Rovi's highest 3-Year average Operating Cash Flow per Share Growth Rate was 164.60% per year. The lowest was -34.50% per year. And the median was 14.50% per year.
LABFF's 3-Year OCF Growth Rate is ranked worse than 69.03% of 762
companies
in the Drug Manufacturers industry
Industry Median: 7.15
vs LABFF: -6.30
Laboratorios Farmaceuticos Rovi Operating Cash Flow per Share Related Terms
Laboratorios Farmaceuticos Rovi Operating Cash Flow per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi Operating Cash Flow per Share Chart
LABFF vs ZTS, UTHR, VTRS: Operating Cash Flow per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi Price-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.77
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Operating Cash Flow per Share of $5.77 mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a Operating Cash Flow per Share of $5.77 as of Jun. 2026. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #526 out of 762 companies in the Drug Manufacturers industry, placing it in the top 69%.
Is Laboratorios Farmaceuticos Rovi's Operating Cash Flow per Share too high?
Laboratorios Farmaceuticos Rovi's current Operating Cash Flow per Share is $5.77. The Drug Manufacturers industry median Operating Cash Flow per Share is 7.15. Laboratorios Farmaceuticos Rovi's value of $5.77 is 19.3% below this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #526 out of 762 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Operating Cash Flow per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #526 out of 762 companies for Operating Cash Flow per Share. This places Laboratorios Farmaceuticos Rovi in the lower half of its industry. The industry median Operating Cash Flow per Share is 7.15. Laboratorios Farmaceuticos Rovi's value of $5.77 is 19.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Cash Flow per Share for a Drug Manufacturers company?
The median Operating Cash Flow per Share among Drug Manufacturers companies is 7.15, based on 762 companies in the industry. Companies in the top quartile (top 25%) have a Operating Cash Flow per Share significantly above this median, while those in the bottom quartile fall well below. However, Operating Cash Flow per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current Operating Cash Flow per Share of $5.77 is 19.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Cash Flow per Share mean?
A high Operating Cash Flow per Share can signal that a stock is expensive relative to its fundamentals. Operating cash flow per share equals the per-share amount of cash flow from operations. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median Operating Cash Flow per Share is 7.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current Operating Cash Flow per Share is $5.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Operating Cash Flow per Share of $5.77. The stock's GF Value™ is $83.60, compared to a current price of $90.61 — trading 8.4% above its estimated fair value. The current Operating Cash Flow per Share is $5.77 and 19.3% below the Drug Manufacturers industry median of 7.15. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Cash Flow per Share calculated?
Operating Cash Flow per Share is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Operating Cash Flow per Share is $5.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of $90.61 is trading 8.4% above its estimated GF Value™ of $83.60.
Key valuation signals for LABFF:
Operating Cash Flow per Share: $5.77
GF Value™: $83.60 vs. price of $90.61 (8.4% above fair value)
Industry Position: 19.3% below the Drug Manufacturers median (#526 of 762)
No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi Business Description
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
89GF Score
Get the complete analysis for LABFF
Operating Cash Flow per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABFF has been successfully added to your 
